Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain

Sałat, Kinga; Kołaczkowski, Marcin; Furgała, Agata; Rojek, Adriana; Śniecikowska, Joanna; Varney, Mark A.; Newman‐Tancredi, Adrian

doi:10.1016/j.neuropharm.2017.07.022

Cited by 43 publications

(42 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the present experiment confirmed that in mice, similarly to humans, oxaliplatin induced cold allodynia-a core symptom of neuropathic pain caused by this cytotoxic drug. After a single dose of oxaliplatin, cold allodynia was persistent and it was maintained for at least 7 days, which is consistent with the previous reports (Furgała, Fijałkowski, Nowaczyk, Sałat, & Sałat, 2018;Han, Kuo, Nicholson, Corradinni, & Smith, 2018;Kono et al, 2013;Nakagawa & Kaneko, 2017;Sałat, Furgała, & Sałat, 2019;Sałat et al, 2017).…”

Section: Discussionsupporting

confidence: 92%

“…In addition to its clinical utility, oxaliplatin is also used in pharmacological laboratories to induce a rodent model of CIPN‐related neuropathic pain that could be utilized in the search for novel therapies for CIPN prevention (Ohsawa et al., ) and treatment (Andoh, Kitamura, & Kuraishi, ; Deuis et al., ; Jiang et al., ; Kim et al., ; King et al., ; Pańczyk et al., ; K. Sałat et al., , ; Sałat & Sałat, ; Yoon, Lee, Roh, & Oh, ). To assess the effect of oxaliplatin on tactile allodynia, researchers worldwide take advantage of using von Frey filaments as an easy‐to‐use method.…”

Section: Introductionmentioning

confidence: 99%

“…In addition to its clinical utility, oxaliplatin is also used in pharmacological laboratories to induce a rodent model of CIPN-related neuropathic pain that could be utilized in the search for novel therapies for CIPN prevention (Ohsawa et al, 2014) and treatment (Andoh, Kitamura, & Kuraishi, 2015;Deuis et al, 2014;Jiang et al, 2016;Kim et al, 2016;King et al, 2017;Pańczyk et al, 2018;K. Sałat et al, 2014K. Sałat et al, , 2017Sałat & Sałat, 2015;Yoon, Lee, Roh, & Oh, 2018).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

2019

Self Cite

View full text Add to dashboard Cite

Oxaliplatin is a third‐generation, platinum‐based derivative used to treat advanced colorectal cancer. Within the patient population on oxaliplatin therapy, a lower incidence of hematological adverse effects and gastrointestinal toxicity is noted, but severe neuropathic pain episodes characterized by increased cold and tactile hypersensitivity are present in ~95% of patients. This drug is also used to induce a rodent model of chemotherapy‐induced peripheral neuropathy (CIPN)‐related neuropathic pain which is widely used in the search for novel therapies for CIPN prevention and treatment. This paper provides a step‐by‐step, detailed description of the prevention and intervention protocols used in our laboratory for the assessment of oxaliplatin‐induced cold allodynia in mice. To establish cold sensitivity in mice, the cold plate test was used. Latencies to pain reaction in response to cold stimulus (2.5°C) for vehicle‐treated non‐neuropathic mice, vehicle‐treated mice injected with oxaliplatin (neuropathic control), and oxaliplatin‐treated mice treated additionally with duloxetine are compared. Duloxetine is a serotonin/noradrenaline reuptake inhibitor which was found to produce significant pain relief in patients with CIPN symptoms. In our present study, duloxetine administered intraperitoneally at the dose of 30 mg/kg served as a model antiallodynic drug which attenuated or partially prevented cold allodynia caused by oxaliplatin.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although 5-HT 2A receptors in the spinal cord dorsal horn contribute to the suppression of neuropathic pain [ 68 , 69 , 70 ], the inhibitory effects of systemically administered SSRIs on hyperalgesia after nerve injury are stronger when spinal 5-HT 2A receptors are disrupted from their associated PDZ proteins by intrathecal injection of a peptide (TAT-2ASCV) [ 71 ]. Systemic administration of a 5-HT 1A receptor agonist (NLX-112) strongly inhibits inflammatory pain, but is less effective against neuropathic pain [ 72 ].…”

Section: The Role Of 5-htmentioning

confidence: 99%

Analgesic Mechanisms of Antidepressants for Neuropathic Pain

Obata

2017

IJMS

281

203

View full text Add to dashboard Cite

Tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors are used to treat chronic pain, such as neuropathic pain. Why antidepressants are effective for treatment of neuropathic pain and the precise mechanisms underlying their effects, however, remain unclear. The inhibitory effects of these antidepressants for neuropathic pain manifest more quickly than their antidepressive effects, suggesting different modes of action. Recent studies of animal models of neuropathic pain revealed that noradrenaline is extremely important for the inhibition of neuropathic pain. First, increasing noradrenaline in the spinal cord by reuptake inhibition directly inhibits neuropathic pain through α2-adrenergic receptors. Second, increasing noradrenaline acts on the locus coeruleus and improves the function of an impaired descending noradrenergic inhibitory system. Serotonin and dopamine may reinforce the noradrenergic effects to inhibit neuropathic pain. The mechanisms of neuropathic pain inhibition by antidepressants based mainly on experimental findings from animal models of neuropathic pain are discussed in this review.

show abstract

“…A particular category of drugs includes SRIs with double mechanism: 5-HT reuptake inhibition and interaction with 5-HT receptors. Animal studies have suggested that these receptors are included in the descending pain inhibitory systems [94,95], and their activation is involved in reducing the acute nociceptive and neuropathic pain [96].…”

Section: Double Function Serotonin Reuptake Inhibitorsmentioning

confidence: 99%

Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management

Onuţu¹,

Dîrzu²,

Petrișor³

2019

Serotonin

View full text Add to dashboard Cite

Serotonin has a particular place in the modulation of pain. Experimental studies have described 5-HT1-7 receptors and their effects on facilitation or inhibition of nociceptive input. Selective serotonin reuptake inhibitors (SSRIs) and serotoninnorepinephrine reuptake inhibitors showed efficient and safer than tricyclic antidepressants in neuropathic pain. Although there is evidence regarding the beneficial impact of SSRIs in the multimodal acute pain management, studies are still searching for the potentially favorable effect of these drugs in the prevention of chronic postoperative pain. The scope of this chapter would be to update the knowledge regarding serotonin involving in pain pathways and to highlight the importance and contribution of serotonin reuptake inhibitors in the multimodal pain management schemes.

show abstract

Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain

Cited by 43 publications

References 41 publications

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice

Analgesic Mechanisms of Antidepressants for Neuropathic Pain

Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management

Contact Info

Product

Resources

About